8 860

Cited 12 times in

Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.

Authors
 Jae Hoon Moon  ;  Hae Jin Kim  ;  Soo Kyung Kim  ;  Eun Seok Kang  ;  Byung Wan Lee  ;  Chul Woo Ahn  ;  Hyun Chul Lee  ;  Bong-Soo Cha 
Citation
 METABOLISM-CLINICAL AND EXPERIMENTAL, Vol.60(2) : 165-172, 2011 
Journal Title
METABOLISM-CLINICAL AND EXPERIMENTAL
ISSN
 0026-0495 
Issue Date
2011
MeSH
Abdominal Fat/drug effects* ; Abdominal Fat/metabolism ; Adult ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use* ; Blood Glucose/drug effects ; C-Reactive Protein/analysis ; Cholesterol/blood ; Diabetes Mellitus, Type 2/drug therapy* ; Drug Therapy, Combination ; Fasting/metabolism ; Female ; Glycated Hemoglobin A/analysis ; Humans ; Hypoglycemic Agents/therapeutic use* ; Insulin/blood ; Male ; Metformin/therapeutic use ; Middle Aged ; Sulfonylurea Compounds/therapeutic use ; Thiazolidinediones/therapeutic use* ; Triglycerides/blood
Abstract
Thiazoledinedione is known to have an anti-inflammatory effect besides a hypoglycemic effect. We investigated changes in high-sensitivity C-reactive protein (hsCRP), a proinflammatory marker, after pioglitazone treatment in association with the resulting changes in various metabolic and anthropometric parameters. A total of 93 type 2 diabetes mellitus patients (47 men and 46 women; mean age, 50.0 ± 10.8 years) who were being treated with a stable dose of sulfonylurea or metformin were enrolled in the study. Pioglitazone (15 mg/d) was added to their treatment regimen for 12 weeks, and metabolic and anthropometric measurements were taken before and after pioglitazone treatment. Pioglitazone treatment for 12 weeks decreased serum hsCRP levels (0.83 [1.14] to 0.52 [0.82] mg/L, P < .001) and improved glycemic control (fasting glucose, P < .001; glycosylated hemoglobin, P < .001) and lipid profiles (triglyceride, P = .016; high-density lipoprotein cholesterol, P < .001). Between responders and nonresponders to the hsCRP-lowering effect of pioglitazone, there were significant differences in baseline hsCRP levels and changes in the postprandial glucose and the ratio of visceral fat thickness (VFT) to subcutaneous fat thickness (SFT) (P = .004, .011, and .001, respectively). The percentage change in hsCRP levels after treatment was inversely correlated with baseline hsCRP levels (r = -0.497, P < .001) and directly correlated with the change in postprandial glucose (r = 0.251, P = .021), VFT (r = 0.246, P = .030), and VFT/SFT ratio (r = 0.276, P = .015). Logistic regression analysis revealed that the hsCRP-lowering effect of pioglitazone was affected by baseline hsCRP levels (odds ratio [OR] = 7.929, P = .007) as well as changes in postprandial 2-hour glucose (OR = 0.716, P = .025) and VFT/SFT ratio (OR = 0.055, P = .009). In conclusion, treatment with pioglitazone produced an anti-inflammatory effect, decreasing serum hsCRP levels; and a decrease in the VFT/SFT ratio was independently and most strongly associated with the hsCRP-decreasing effect. These results suggest that abdominal fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.
Full Text
http://www.sciencedirect.com/science/article/pii/S0026049509005198
DOI
10.1016/j.metabol.2009.12.007
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Moon, Jae Hoon(문재훈)
Ahn, Chul Woo(안철우) ORCID logo https://orcid.org/0000-0003-3733-7486
Lee, Byung Wan(이병완) ORCID logo https://orcid.org/0000-0002-9899-4992
Lee, Hyun Chul(이현철)
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/92973
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links